Results 91 to 100 of about 384,305 (217)

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Coronary endothelial function testing may improve long-term quality of life in subjects with microvascular coronary endothelial dysfunction

Open Heart, 2019
Aim Angina pectoris in the absence of obstructive coronary artery disease (CAD) is common and is associated with poor quality of life (QOL). Coronary microvascular endothelial dysfunction is associated with myocardial ischaemia and is a common cause of ...
Ryan Lennon, Andreas J Flammer, Jing Li, Charanjit S Rihal, Martin Reriani, Jessica Duhé, Rajiv Gulati, Jonella M Tilford, Abhiram Prasad, Lilach O Lerman, Amir Lerman   +10 more
doaj   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Treatment of Angina and Microvascular Coronary Dysfunction [PDF]

Current Treatment Options in Cardiovascular Medicine, 2010
Microvascular coronary dysfunction (MCD) is an increasingly recognized cause of cardiac ischemia and angina that is diagnosed more commonly in women. Patients with MCD present with the triad of persistent chest pain, ischemic changes on stress testing, and no obstructive coronary artery disease on cardiac catheterization.
Arang, Samim, Lynn, Nugent, Puja K, Mehta, Chrisandra, Shufelt, C Noel, Bairey Merz   +4 more
openaire   +2 more sources

Randomized, crossover, controlled trial on the modulation of cardiac coronary sinus hemodynamics to develop a new treatment for microvascular disease: Protocol of the MACCUS trial

Frontiers in Cardiovascular Medicine, 2023
BackgroundMicrovascular angina (MVA) is a frequent condition for which our understanding of the disease pathophysiology and therapeutic perspectives remain unsatisfactory.
Helen Ullrich, Helen Ullrich, Maximilian Olschewski, Maximilian Olschewski, Thomas Münzel, Thomas Münzel, Tommaso Gori, Tommaso Gori   +7 more
doaj   +1 more source

Coronary microvascular dysfunction in angina and no-obstructive coronary arteries: Pathophysiology, diagnosis, novel markers and therapy.

Kardiologia polska
Coronary microvascular dysfunction encompasses a wide variety of structural and/or functional abnormalities of the coronary microcirculation which are key determinants of myocardial ischemia in patients with angina and non-obstructive coronary artery ...
Domenico Galante, G. La Vecchia, A. M. Leone, Filippo Crea   +3 more
semanticscholar   +1 more source

Menopause hormone therapy in women with cardiovascular risk factors or established ischemic heart disease: A joint FIGO and WHF position paper

International Journal of Gynecology &Obstetrics, EarlyView.
Integrated approach to menopausal hormone therapy in women with cardiovascular risk factors or established ischemic heart disease, from early treatment initiation and risk stratification to individualized therapy, multidisciplinary follow‐up, and health‐system recommendations.
Chiara Benedetto, Martha Gulati, Suvarna S. Khadilkar, Angela H. E. M. Maas, Federica Frezet, Gláucia Maria Moraes de Oliveira, Andrea R. Genazzani, Hema Divakar, Athena Poppas, on behalf of the World Heart Federation (WHF) and the International Federation of Gynecology and Obstetrics (FIGO)   +9 more
wiley   +1 more source

Coronary Sinus Reducer: History, Current Applications, and Future Perspectives

Reviews in Cardiovascular Medicine
The coronary sinus reducer (CSR) is a percutaneous device designed to improve coronary blood flow and alleviate symptoms of refractory angina in patients with severe coronary artery disease (CAD) who are unsuitable for revascularization therapy.
Fabrizio Ugo, Marco Franzino, Chiara Cavallino, Mohamed Abdirashid, Ludovica Maltese, Francesco Rametta   +5 more
doaj   +1 more source

Human biomarker navigator

iMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li, Qian Zhang, Zijie Wang, Zeping Gui, Jing Liu, Jingda Li, Maojun Jiang, Zukang Chang, Qingqing Han, Bendong Yang, Tariq Saeed, Jun Li, Jinghan Jia, Chenghu Song, Tong Shao, Tianhuan Peng, Xueying Zhang, Pingping Guo, Jun Luo, Gangao Yang, Yuan Wan, Gokhan Zengin, Quan Yuan, Lingru Li, Xiaohui Fan, Yang Luo, Lvyun Zhu, Yanfei Zheng, Wenjun Mao, Wenlong Sun   +29 more
wiley   +1 more source

Sex-Specific Factors in Microvascular Angina [PDF]

Canadian Journal of Cardiology, 2014
In women presenting for evaluation of suspected ischemic symptoms, a diagnosis of normal coronary arteries is 5 times more common than it is in men. These women are often labelled as having cardiac syndrome X, and a subset of them have microvascular angina caused by microvascular coronary dysfunction (MCD).
Tara, Sedlak, Mona, Izadnegahdar, Karin H, Humphries, C Noel, Bairey Merz   +3 more
openaire   +2 more sources